Day: August 5, 2024

Record Second Quarter 2024 Revenue Increased 33% Year-over-Year WARSAW, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second quarter ended June 30, 2024. Second Quarter 2024 and Recent Business Highlights Helped a record 32,000 children in the second quarter of 2024, an increase of 52% from the second quarter 2023 Generated record total revenue of $52.8 million for the second quarter of 2024, up 33% from $39.6 million in second quarter 2023; domestic revenue increased 39% and international revenue increased 16% in the quarter Grew worldwide Trauma & Deformity revenue 37%, worldwide Scoliosis revenue 26%; Sports Medicine/Other revenue...

LA JOLLA, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) — Palomar Holdings, Inc. (NASDAQ:PLMR) (“Palomar” or “Company”) reported net income of $25.7 million, or $1.00 per diluted share, for the second quarter of 2024 compared to net income of $17.6 million, or $0.69 per diluted share, for the second quarter of 2023. Adjusted net income(1) was $32.0 million, or $1.25 per diluted share, for the second quarter of 2024 as compared to $21.8 million, or $0.86 per diluted share, for the second quarter of 2023. Second Quarter 2024 Highlights Gross written premiums increased by 40.4% to $385.2 million compared to $274.3 million in the second quarter of 2023 Net income of $25.7 million, compared to $17.6 million in the second quarter of 2023 Adjusted net income(1) of $32.0 million, compared to $21.8 million in the second quarter of 2023 Total...

FORT MYERS, Fla. , Aug. 05, 2024 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico”, the “Company”, “we”, “us” or “our”) (Nasdaq: ALCO) today announced financial results for the third quarter of fiscal year 2024 and the nine months ended June 30, 2024, the highlights of which are as follows: The Company previously announced that it entered a new three-year agreement to sell oranges to Tropicana at prices that are approximately 33% to 50% higher, over the life of the contract, than the average price for all the citrus fruit sold to Tropicana last season. The Company has now treated substantially all of its producing trees with Oxytetracycline (“OTC”) and anticipates that these 4.5 million trees will support meaningful production growth in the 2024-25 harvest season. The Company previously announced that it has continued to commit to its real...

ATHENS, Greece, Aug. 05, 2024 (GLOBE NEWSWIRE) — Okeanis Eco Tankers Corp. (the “Company” or “OET”) (NYSE:ECO / OSE:OET), will report unaudited interim condensed results for the second quarter and first half year ended June 30, 2024, on Friday, August 9, 2024, and a webcast/teleconference will be held at 14:30 CET. Participants may access the webcast using the following link: https://events.q4inc.com/attendee/514653447 Or via conference call using the below dial-in details:Standard International Access: +44 20 3936 2999USA: +1 646 664 1960Norway: +47 815 03 308Password: 450545 The presentation material, which will be used in the webcast/teleconference, will be available for download from the Investor Relations section at www.okeanisecotankers.com prior to the live webcast/teleconference. Contacts Company Iraklis Sbarounis, CFO...

Increases 2024 revenue guidance to $165 million – $167 millionExpects to achieve positive Adjusted EBITDA in Fourth Quarter 2024 SANTA CLARA, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights (comparisons are to the prior year period) Worldwide revenue of $40.0 million, representing growth of ~20%   U.S. revenue of $37.8 million, representing growth of ~21% Gross margin of ~79% Net loss of $8.9 million, representing an improvement of ~20% Adjusted EBITDA loss of $2.7 million, representing an improvement of ~43% Ended the quarter with $151.5 million in cash and equivalents Recent Operational Highlights (comparisons are to the...

PEMBROKE, Bermuda, Aug. 05, 2024 (GLOBE NEWSWIRE) — James River Group Holdings, Ltd. (“James River” or the “Company”) (NASDAQ: JRVR) today reported the following results for the second quarter 2024 as compared to the same period in 2023:   Three Months EndedJune 30,   Three Months EndedJune 30, ($ in thousands, except for share data)   2024     per diluted share     2023   per diluted share Net income from continuing operations available to common shareholders $ 11,853     $ 0.31     $ 9,504   $ 0.25 Net (loss) income from discontinued operations   (6,853 )   $ (0.18 )     3,785   $ 0.10 Net income available to common shareholders   5,000     $ 0.13       13,289   $ 0.35 Adjusted net operating income1   12,664     $ 0.33       6,647   $ 0.18                             The Company closed...

Second quarter revenue of $79.8 million, representing a decrease of 4% year-over-year. Second quarter gross margin of 70.4% and an increase in gross profit of 1% year-over-year. Active Buyers of 1.7 million and Orders of 1.7 million in Q2 2024, representing a decrease of 3% and a decrease of 6%, respectively, year-over-year. Evaluating strategic alternatives for its European business; providing Q3, Q4, and updated FY 2024 guidance for both consolidated and U.S. only operations. OAKLAND, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) — ThredUp Inc. (Nasdaq: TDUP, LTSE: TDUP), one of the largest online resale platforms for apparel, shoes, and accessories, announced today its financial results for the second quarter ended June 30, 2024 and updated full year 2024 financial outlook. “While this quarter presented challenges in both the U.S....

ALISO VIEJO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) — (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2024. Key Quarterly Highlights Reported second quarter 2024 revenue of $34.9 million, an increase of 68% compared to the second quarter of 2023, reflecting: The sale of 24,214 Light Adjustable Lenses (LAL™/LAL+™), representing a 92% increase in procedure volume compared to the second quarter of 2023; The sale of 78 Light Delivery Devices (LDD™s), representing a 16% increase in unit sales compared to the second quarter of 2023 and expanding the installed base to 810 LDDs at the end of the quarter, representing a 55% increase...

–The Phase 3 ENLIGHTEN-Fibrosis trial in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and the Phase 3 ENLIGHTEN-Cirrhosis trial in patients with compensated cirrhosis (F4) are enrolling patients– –Phase 3 ENTRUST trial for patients with severe hypertriglyceridemia (SHTG) continues to enroll patients and topline data is expected in 2025– SAN FRANCISCO, Aug. 05, 2024 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the second quarter ended June 30, 2024. “We are thrilled to have initiated two pivotal Phase 3 trials addressing non-cirrhotic MASH (ENLIGHTEN-Fibrosis in F2-F3) and MASH...

MINNEAPOLIS, Aug. 05, 2024 (GLOBE NEWSWIRE) — Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights: Total revenue increased 7% year-over-year to $73.2 million Lymphedema product revenue increased 8% year-over-year Airway clearance product revenue increased 2% year-over-year Net income of $4.3 million versus a net loss of $0.1 million in Q2 2023 Adjusted EBITDA of $9.1 million versus $6.1 million in Q2 2023 Operating cashflow of $13.1 million, ended Q2 2024 with $73.6 million in cash and cash equivalents 510(k) clearance for Nimbl system, our next generation lymphedema therapy platform Appointed Sheri Dodd...